Oculis at guggenheim healthcare conference: precision medicine push

On November 9, 2026, Oculis Holding (OCS) presented its strategic plan at the 3rd Annual Guggenheim Healthcare Innovation Conference. The company's focus is on two late-stage drug programs and maintaining a strong cash reserve. Oculis is developing a precision medicine approach for dry eye treatment and investigating a neuroprotective drug for optic neuritis.

The company's shares rose 4.01% to $7.79 following the conference, despite being far below its 52-week high of $34.475. Oculis has $252 million in cash and a CHF 100 million debt facility, which will support its operations through the second half of 2029. Phase III studies for licaminlimab and privosegtor are nearing completion, with expected results in the coming weeks.

Licaminlimab is Oculis' lead dry eye candidate, targeting TNFR1-positive patients with a TNF inhibitor. The company aims to move from trial-and-error prescribing to a "test and treat" model using a biomarker to identify high-response patients. In neuro-ophthalmology, privosegtor could become a platform therapy for optic neuritis and potentially MS relapse and NAION.

Management highlighted Oculis' strong financial position, with more cash than debt on its balance sheet, a robust current ratio of 10.41, and a significant cash burn rate.